comparative effects of low-dose rosuvastatin, placebo and dietary supplements on lipids

Last edited 11/2022 and last reviewed 12/2022

Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers

• a study compared the efficacy of a low-dose statin with placebo and six common supplements in impacting lipid and inflammatory biomarkers
  
  
• was a single-center, prospective, randomized, single-blind clinical trial among adults with no history of atherosclerotic cardiovascular disease (ASCVD), an LDL-C of 70-189 mg/dL and an increased 10-year risk of ASCVD
  
  
• participants were randomized to 5 mg daily of rosuvastatin, placebo, fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice
  
  
• primary endpoint was the percent change in LDL-C from baseline for rosuvastatin 5 mg daily compared with placebo and each supplement after 28 days. The primary endpoint was evaluated in a hierarchical fashion with rosuvastatin first compared with placebo, then each supplement in a prespecified order using ANCOVA
  
  
• study results
  • 190 participants completed the study
  • percent LDL-C reduction with rosuvastatin was greater than all supplements and placebo (p <0.001)
  • difference in LDL-C reduction with rosuvastatin compared with placebo was -35.2% (95% confidence interval, -41.3 to -29.1, p <0.001)
  • none of the dietary supplements demonstrated a significant decrease in LDL-C compared with placebo
  • adverse event rates were similar across study groups
    
    
• study authors concluded:
  • among individuals with increased 10-year risk for ASCVD, rosuvastatin 5 mg daily lowered LDL-C significantly more than placebo, fish oil, cinnamon, garlic, turmeric, plant sterols, and red yeast rice

Reference:

• Laffin LJ et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers. J Am Cardiol Nov 06, 2022